Results 151 to 160 of about 2,799 (186)
Some of the next articles are maybe not open access.
Misonidazole—A drug for trial in radiotherapy and oncology
International Journal of Radiation Oncology*Biology*Physics, 1979Abstract Misonidazole is an hypoxic cell radiosensitizer with promise in clinical radiotherapy. The concentrations which may be achieved in plasma, in tumors and in normal tissues are discussed. The toxic effects of misonidazole are described and schemes for the safe administration in man detailed.
S, Dische +4 more
openaire +2 more sources
Biochemical Pharmacology, 1980
Abstract Misonidazole [1-(2-nitroimidazol-1-yl)-3-methoxypropan-2-ol; Ro 07-0582] selectively sensitizes hypoxic cells to radiation and is undergoing clinical trial in the radiation treatment of solid tumours. It has been suggested that the glucocorticoid hormone dexamethasone may reduce the incidence of neurotoxicity, the dose-limiting side effect ...
openaire +2 more sources
Abstract Misonidazole [1-(2-nitroimidazol-1-yl)-3-methoxypropan-2-ol; Ro 07-0582] selectively sensitizes hypoxic cells to radiation and is undergoing clinical trial in the radiation treatment of solid tumours. It has been suggested that the glucocorticoid hormone dexamethasone may reduce the incidence of neurotoxicity, the dose-limiting side effect ...
openaire +2 more sources
Clinical studies with misonidazole.
The British journal of cancer. Supplement, 1978The preliminary details of a randomized clinical trial of misonidazole for the radiotherapy of Grades 3 and 4 cerebral astrocytoma are described. Plasma concentrations of misonidazole and its O-demethylated metabolite, determined by high-pressure liquid chromatography analysis, are reported for 8 patients with astrocytoma, 1 with carcinoma of the ...
C R, Wiltshire +3 more
openaire +1 more source
Reductive metabolism and DNA binding of misonidazole
Toxicology and Applied Pharmacology, 1989Misonidazole (1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol) is an experimental anticancer drug. Reductive metabolism is thought to be important for the cytotoxicity of misonidazole. In this study, the DNA binding of misonidazole was examined after chemical and enzymatic reduction.
openaire +2 more sources
Plasma concentrations of misonidazole.
Strahlentherapie, 1981The plasma concentrations of misonidazole doses between 0.6 and 2.0 g/m2 were analyzed in respect to the variation within the same patient and between different patients. Peak plasma levels were observed after 2 hours. The mean plasma levels of misonidazole only at 3 hours were 23.8, 47.0 and 76.5 microgram/ml after misonidazole doses of 0.6, 1.2 and 2.
G, Notter, U, Rylander, I, Turesson
openaire +1 more source
Clinical experience with misonidazole.
The British journal of cancer. Supplement, 1978A total of 62 patients with advanced tumours have now been treated by a fractionated course of radiotherapy, with misonidazole. The prime purpose of the administration of the drug to these patients was to determine safe dosage and suitable regimes for use in clinical radiotherapy.
S, Dische, M I, Saunders
openaire +1 more source
Misonidazole levels following misonidazole and hyperbaric oxygen exposure
International Journal of Radiation Oncology*Biology*Physics, 1987G. Blekkenhorst, R. Sealy, S. Cridland
openaire +1 more source